Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors

Prostate

Volumn 44, Issue 2, 2000, Pages 156-163

  Leung, Simon Y L ^a,b   Jackson, John ^b   Miyake, Hideaki ^a   Burt, Helen ^b   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hormone refractory; LNCaP tumor model; Micellar paclitaxel; Prostate cancer

Indexed keywords

PACLITAXEL; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; DRUG FORMULATION; DRUG MECHANISM; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; ELECTROPHORESIS, AGAR GEL; GENTIAN VIOLET; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; ORCHIECTOMY; PACLITAXEL; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0034234649     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8     Document Type: Article

References (29)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer [Suppl] 1993;72:3888-3895.
3. Eisenberger MA, Bezerdijian L, Kalash S. A critical assessment of the role of chemotherapy for endocrine-resistant prostate carcinoma. Urol Clin North Am 1987;14:695-706.
4. Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
6. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-487.
7. Kumar N. Taxol-induced polymerization of purified tubulin: mechanism of action. J Biol Chem 1981;256:435-141.
8. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-1259.
9. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-9556.
10. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-4511.
11. Haldar S, Chintapalli J, Croce CM. Taxol induced Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56:1253-1255.
12. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 11:151-157.
13. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
14. Dorr RT. Pharmacology and toxicity of Cremophor EL diluent. Ann Pharmacother 1994;28:11-26.
15. Goldspiel BR. Pharmaceutical Issues: Preparation, administration, stability, and compatibility with other medications. Ann Pharmacother 1994;28:23-26.
16. Onetta N, Canett R, Winograd B, et al. J Natl Cancer Inst Monogr 1993;15:131-139.
17. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-1268.
18. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20:1-15.
19. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of Taxol. Int J Pharm 1996;132:195-206.
20. Gleave ME, Hsieh JT, Wu HC, Chung LWK. Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-1605.
21. Sellins K, Cohen J. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987;39: 3199-3206.
22. Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblast. Cancer Res 1991;51:3753-3761.
23. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
24. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3: 1013-1021.
25. Torti FM, Carter SK. The chemotherapy of prostate adenocarcinoma. Ann Intern Med 1980;92:681-689.
26. Esienberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-841.
27. Yagoda A, Petrylak DP. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
28. Furuya Y, Krajewski S, Epstein JI, Reed JC, Issacs JT. Expression of bcl-2 and progression of human and rodent prostate cancers. Clin Cancer Res 1996;2:389-398.
29. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-233.